


How to use CONNECT

The CONNECT AI-driven platform, developed at the University “G. D’Annunzio”, is a sophisticated tool designed to facilitate and enhance research collaborations within the INGENIUM network. Funded by the European Commission as part of the “Boosting INGENIUM For Excellence – BI4E” project, CONNECT primarily helps researchers find suitable collaborators. It leverages artificial intelligence to analyze and match research interests. The CONNECT platform has evolved to emphasize the search for multidisciplinary collaborations. This strategic shift reflects a growing recognition of the importance of interdisciplinary approaches in advancing research and solving complex problems. Below is an explanation of how to use it:

Visit the CONNECT page: Begin by going to the CONNECT platform's website at <https://connect.unich.it> This is where you'll input your information and use the tool.

Input Research Interests or Calls: Once on the CONNECT website, enter detailed information about your research activities or specific research calls you're interested in applying to. Provide comprehensive details (up to 500 characters) about your research topics, methodologies, desired outcomes, etc. The more detailed your input, the better CONNECT can identify suitable collaborators. Select the number of researchers you want to be shown. The minimum number is 5, and the maximum is 20.




The screenshot shows the BI4E CONNECT platform interface. At the top, the BI4E logo is displayed. Below it, there is a search bar with a magnifying glass icon and a pink arrow button. To the left of the search bar, there is a control for the number of researchers, labeled "N. Researchers" with a range of "Min 5 / Max 20" and a slider set to "5". Below the search bar, there are two informational boxes: "Start from the research call" and "More detail for greater match". The footer contains copyright information and links for "Privacy Policy", "Ingenium University", and "BI4E".

Review Suggestions (Takes a Few seconds/minutes): After entering your information, allow CONNECT a few minutes to process it. The tool will then suggest up to 20 potential research



This project has received funding from the European Union’s HORIZON-WIDERA-2021-ACCESS-05-01-European Excellence Initiative under Grant Agreement No. 101071321 – BI4E

collaborators, based on a match between your input and the abstracts published by other researchers in the network, as found in databases like SCOPUS and ORCID.



Check Researcher Details: Each suggested researcher's name will be displayed along with their affiliation and ORCID. Next to each researcher's ORCID, there's an arrow icon. Clicking on this arrow reveals the three most relevant abstracts that align with the user's research interests. This feature offers a quick and direct insight into the potential collaborator's work, making it easier to assess the relevance and depth of the match. When a user clicks on the arrow next to a researcher's ORCID ID, they not only see the three most relevant abstracts but also find key words or phrases underlined within these abstracts. These underlined texts are the terms that directly match with the user's inputted research interests, highlighting the specific relevance of each abstract.

20 researchers identified

Why we're suggesting these researches for your research project

This topic refers to the innovation market for Healthcare and Medicine, which affects many citizens and their needs. Several materials specifications and related innovations needs will support this topic such as renewable and recyclable materials, alternative active ingredients, design for circularity, lightweight materials. The topic should address several key policies of the European Union such as Circular Economy Action Plan, EU Chemicals strategy.

- Kati Manskinen**

LAB UNIVERSITY OF APPLIED SCIENCES

ORCID: -
- Guenka Ivanova Petrova**

MEDICAL UNIVERSITY OF SOFIA

ORCID: 0000-0001-8116-5138
- M. L. Avădanei**

UNIVERSITATEA TEHNICA GH. ASACHI DIN IASI

ORCID: 0000-0002-9945-8120
- Maria S. Kamusheva**

MEDICAL UNIVERSITY OF SOFIA

ORCID: 0000-0002-4379-5283
- M. Gavrilescu**

UNIVERSITATEA TEHNICA GH. ASACHI DIN IASI

ORCID: 0000-0002-9663-9316
- Andrei Victor Sandu**

UNIVERSITATEA TEHNICA GH. ASACHI DIN IASI

ORCID: 0000-0002-9292-749X
- Antonea Curteza**

UNIVERSITATEA TEHNICA GH. ASACHI DIN IASI

ORCID: -
- Maria Jordanova Dimitrova**

MEDICAL UNIVERSITY OF SOFIA

ORCID: 0000-0002-4868-7725



Why we're suggesting these researches for your research project

This topic refers to the innovation market for Healthcare and Medicine, which affects many citizens and their needs. Several materials specifications and related innovations needs will support this topic such as renewable and recyclable materials, alternative active ingredients, design for circularity, lightweight materials. The topic should address several key policies of the European Union such as Circular Economy Action Plan, EU Chemicals strategy.

Guenka Ivanova Petrova
MEDICAL UNIVERSITY OF SOFIA ORCID: 0000-0001-8116-5138

Benefits of investment into modern medicines in Central-Eastern European countries

Transferability of current evidence and expressing value of innovative pharmaceuticals according to health system objectives Due to the scarcity of healthcare resources, decision-makers often expect monetary benefits-including cost savings or productivity gain-from innovative medicines. Manufacturers try to fulfill this expectation by expressing the benefits of innovative technologies in monetary units citing approaches from the scientific literature. Unfortunately, currently available evidence has limited relevance and transferability in Central-Eastern European (CEE) countries. This study aims to summarize how innovative pharmaceuticals in CEE countries may contribute to WHO-defined health system objectives, including health gain, equity in health, financial protection, responsiveness, equity in finance and financial sustainability. References in this study are also mainly based on international examples; therefore, additional policy research from CEE countries is necessary to validate assumptions. If CEE politicians can rely on credible arguments based on local research evidence, they may improve long-term strategies and policy decisions related to healthcare innovation. © 2014 Informa UK, Ltd.

Health technology assessment in the balkans: Opportunities for a balanced drug assessment system

Countries in the Balkan region use pharmaco-economic data for decisions about the inclusion of new pharmaceuticals into their positive drug lists, but no predefined frameworks are used and resources for health technology assessment (HTA) are limited. The goal of this analysis is to investigate into possible development directions for the HTA system in the region, and provide some practical recommendations for a sustainable model. For this purpose, the main factors currently influencing HTA in Balkan countries are briefly presented, and possible development strategies are compared. A resourcesaving balanced assessment approach is proposed. It is aligned with available resources and capabilities, and helps access to new pharmaceuticals while ensuring the transparency of decision-making processes and the stability of the pharmaceutical budget.

Proposal for a regulation on health technology assessment in Europe-opinions of policy makers, payers and academics from the field of HTA

Introduction: In January 2018 the European Commission published a Proposal for a Regulation on Health Technology Assessment (HTA): 'Proposal for a Regulation on health technology assessment and amending Directive 2011/24/EU'. A number of stakeholders, including some Member States, welcomed this initiative as it was considered to improve collaboration, reduce duplication and improve efficiency. There were however a number of concerns including its legal basis, the establishment of a single managing authority, the preservation of national jurisdiction over HTA decision-making and the voluntary/mandatory uptake of joint assessments by Member States. Areas covered: This paper presents the consolidated views and considerations on the original Proposal as set by the European Commission of a number of policy makers, payers, experts from pricing and reimbursement authorities and academics from across Europe. Expert commentary: The Proposal has since been extensively discussed at Council and while good progress has been achieved, there are still divergent positions. The European Parliament gave a number of recommendations for amendments. If the Proposal is approved, it

Access ORCID Profiles: Next to each researcher's name, you'll see their ORCID ID. Clicking on this ID will redirect you to the respective ORCID page of that researcher, providing further insight into their work, publications, and academic history.

Understand Affiliation Anomalies: Sometimes, the affiliation of a suggested researcher may not appear to be from an INGENIUM university. In such cases, it's likely that the researcher is indeed part of an INGENIUM university but their SCOPUS/ORCID profile hasn't been updated.

Handling Missing ORCID IDs: If an ORCID ID is not displayed for a researcher, it usually indicates that they haven't linked their ORCID to their SCOPUS ID. This lack of linkage doesn't diminish the potential value of their collaboration.

Follow-Up Actions: After reviewing the suggestions, you can take further steps like contacting the researchers, exploring their previous work, or discussing potential collaboration opportunities.

By following these steps, you can effectively use the CONNECT tool to find potential research collaborators within the INGENIUM network.

If you experience any problems with CONNECT do not hesitate to contact:

Francesca Scozzari: francesca.scozzari@unich.it

Gianluca Amato: gianluca.amato@unich.it

